This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Two Undervalued China Pharma Stocks

NEW YORK ( TheStreet) -- Two China pharmaceutical stocks China Sky One Medical (CSKI) and Skystar Bio-Pharmaceuticals (SKBI - Get Report) reported robust earnings for the second quarter ended June 30. The stocks gained 4.2% and 11.5%, respectively, on the day the results were announced. Surprisingly, since then, China Sky One Medical has shed 12.8%, while Skystar has declined 16%. As there were no unfavorable developments that took place within these companies, one could imagine that investors preferred exiting the stocks on a rally.

This decline compares to the 5% drop of the S&P 500, a 4% decrease in Bank of New York (BNY) China ADR Index, and a 3% fall on the NYSE Arca China Index during the same period. Both BNY and Arca China Index track the performance of China ADRs listed on the U.S. exchange.

The drop in stock prices offers investors an attractive buying opportunity. Moreover, these stocks seem to be relatively undervalued as they are trading at PEs of 4.27 and 4.47, respectively, lower than peers such as Pfizer (PFE - Get Report), Merck (MRK - Get Report) and Novartis AG, (NVS - Get Report), which are trading at PEs of 12.88, 8.29 and 12.50, respectively.

China's pharmaceutical market, currently the sixth-largest globally, is valued at more than $25 billion and is expected to rank third by 2011, based on the IMS Health estimates. According to a report by Pharmaceutical Drug Manufacturers, China's pharmaceutical market is expected to grow at more than 20% annually, contributing 21% to overall global growth through 2013.

During the second quarter, China Sky One Medical reported adjusted earnings of 60 cents per share, topping analysts' estimates of 53 cents per share. Revenue grew 26.7% year-over-year to $40.76 million from $32.18 million. The company does not have any debt obligations. It did not provide an update on its FY 2010 guidance as it is currently in contract renewal discussions with a few distributors.

On August 31, Global Hunter Securities maintained a buy rating on the stock, lowering its price estimates from $20 to $15 on concerns that the negotiations with distributors may not necessarily yield positive results.

However, the company has already been addressing this issue by training a professional team to better co-operate with its distributors. It is also creating new policies and incentives to encourage better performance by the distributors.

Skystar Bio-Pharmaceuticals, on the other hand, reported earnings of 33 cents per share as opposed to a loss of 3 cents per share a year ago. Earnings more than doubled from the previous quarter. Analysts expected the company to report earnings of 29 cents per share.

Revenue soared 32% year-over-year to $8.26 million. For the full year, the company reaffirmed its revenue guidance of $45.5 million to $47.5 million. On August 23, Rodman & Renshaw reiterated a market outperform rating to the stock with a price target of $15, implying a 56% upside over the current levels.

Karvy Global Services (, a subsidiary of the Karvy group (, provides specialized research in asset classes including stocks, mutual funds and insurance to leading Wall Street firms.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CSKI $0.06 -75.00%
MRK $57.48 0.00%
NVS $98.61 0.00%
PFE $34.79 0.00%
SKBI $3.91 0.00%


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs